Abstract
AD is a chronic, symptomatic, inflammatory skin disease that can affect patients’ quality of life (QoL). Greater improvements in QoL have been observed with deeper improvements on the Eczema Area and Severity Index (EASI). In the Heads Up study, 692 adults with moderate-to-severe AD were randomized 1:1 to oral upadacitinib 30 mg once-daily or subcutaneous dupilumab 300 mg every other week. Degree of skin improvement was compared using proportions of patients achieving ≥50%, ≥75%, ≥90%, and 100% EASI improvement from baseline (EASI-50, EASI-75, EASI-90, EASI-100).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
